(ACXP)
0.00
0.00 (0.00%)
Get all premium features to the best stock analysis tool
0.00
0.00 (0.00%)
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company’s lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
| Name | Position |
|---|---|
| Mr. Robert G. Shawah CPA | Co-Founder & CFO |
| Mr. Robert J. DeLuccia | Co-Founder & Executive Chairman |
| Date | Type | Document |
|---|---|---|
| 2026-03-12 | S-8 | tm267891d1_s8.htm |
| 2026-03-09 | 8-K | tm268319d1_8k.htm |
| 2026-02-02 | S-1 | tm264593-1_s1.htm |
| 2025-12-30 | S-3/A | tm2534261d1_s3a.htm |
| 2025-11-12 | 10-Q | acxp-20250930x10q.htm |
| 2025-10-20 | S-1 | tm2528937d1_s1.htm |
| 2025-09-22 | 8-K | tm2526666d1_8k.htm |
| 2025-09-19 | 8-K | tm2526531d1_8k.htm |
| 2025-08-11 | 10-Q | acxp-20250630x10q.htm |
| 2025-08-05 | DEFA14A | tm2521566d3_defa14a.htm |